Outcomes of Patients With Late-Relapse Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Single Institution Experience.

Conclusion: Patients with late-relapse mRCC treated with targeted therapy had prolonged survival that compared favorably to historical controls, and metastases in uncommon sites were noted. PMID: 29230117 [PubMed]
Source: Ochsner Journal - Category: General Medicine Tags: Ochsner J Source Type: research